Jazz Pharmaceuticals gets Cramer backing in CNBC stock call segment

Jazz Pharmaceuticals gets Cramer backing in CNBC stock call segment
Cramer picks Jazz Pharma

Jim Cramer is weighing a fresh set of rapid-fire stock calls as investors look for signals on speculative and rate-sensitive names. In the latest lightning round, he backs Jazz Pharmaceuticals while warning against Apple Hospitality REIT and expressing caution on several other stocks.

Highlights

  • Jim Cramer backs Jazz Pharmaceuticals as a speculative buy, noting profitability despite risk as reported on CNBC's Mad Money segment.
  • Cramer warns Apple Hospitality REIT is unattractive if rates reach 6%, predicting buyers could lose money under this scenario.
  • EchoStar could attract a takeover bid from SpaceX according to recent speculation Cramer flagged, highlighting event-driven upside potential in telecom shares.

Cramer’s latest calls on sector-specific stocks

As reported by CNBC, the “Mad Money” host says he is prepared to say yes to Jazz Pharmaceuticals, describing the stock as speculative but noting that the company does make money.

He takes a negative view on Corteva, saying there is no reason to own it over Vylor. On Onto Innovation, he says he wants to take a harder look because the company operates in process control solutions, a segment he describes as difficult to understand.

For Apple Hospitality REIT, Cramer says the stock is unattractive if interest rates rise to 6%, adding that buyers could lose money under that scenario. He also says he thinks rates will go to 6%.

Takeover speculation and market implications

On EchoStar, Cramer points to a piece he read saying the company could draw a bid from SpaceX, calling the argument compelling even though he has not liked the stock. His comments highlight how takeover speculation can quickly shift sentiment around underperforming companies.

The mix of calls underscores the different pressures facing healthcare, real estate, industrial technology and telecom names. Cramer’s remarks favor profitable businesses and caution against rate-sensitive shares, while also leaving room for event-driven upside where acquisition interest could emerge.

Our earlier coverage of U.S. housing affordability highlighted how elevated mortgage rates and borrowing costs have widened the gap between the income needed to buy a home and the national median. We noted that with 30-year fixed rates hovering around multi-year highs, affordability remains strained even as some listings see price cuts and new-home sales show pockets of resilience.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.